Skip to main content
main-content

Sodium-glucose co-transporter-2 inhibitors

News

03-20-2019 | Peripheral arterial disease | News

DECLARE-TIMI 58 outcomes consistent in people with peripheral artery disease

Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-17-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

Read more

Related topics

Superior

Related

Specific

Opinion

11-14-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

09-12-2018 | Diet | Commentary | Article

Diet–drug interactions: Why two rights can make a wrong

Editorial Board member and Endocrinologist, Sanjay Kalra comments on the issues raised by a clinical case involving sodium glucose cotransporter 2 inhibitor therapy alongside a restrictive diet.

01-16-2018 | Type 1 diabetes | Editorial | Article

Sodium-glucose cotransporter-2 inhibitors for type 1 diabetes: Ready for prime time?

Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.

In depth

11-16-2018 | Dapagliflozin | Feature | Video

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

11-10-2018 | Dapagliflozin | Feature | Video

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

Original research

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-17-2018 | Medications | Review | Article

Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes

Tosur M, Redondo MJ, Lyons SK. Curr Diab Rep 2018; 18: 79. doi: 10.1007/s11892-018-1041-1

Case reports

05-28-2018 | Lifestyle interventions | Case report | Article

Successful management of poorly controlled type 2 diabetes with multidisciplinary neurobehavioral rehabilitation: A case report and review

Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

03-29-2018 | Pregnancy | Case report | Article

Empagliflozin, metformin, and insulin degludec, during pregnancy: A case report

Formoso G et al. Acta Diabetol 2018; 55: 759. doi: 10.1007/s00592-018-1134-y

01-15-2018 | Prader-Willi syndrome | Case report | Article

Effectiveness of sodium-glucose cotransporter-2 inhibitor as an add-on drug to GLP-1 receptor agonists for glycemic control of a patient with Prader–Willi syndrome: A case report

Horikawa Y et al. Diabetes Ther 2018; 9: 421. doi: 10.1007/s13300-018-0369-5

image credits